caa a22 4500 465789544 CHVBK 20180323112019.0 cr unu---uuuuu 170327e19900801xx s 000 0 eng 10.1007/BF00171840 doi (NATIONALLICENCE)springer-10.1007/BF00171840 A phase II study of menogaril (NSC-269148) in colorectal carcinoma [Elektronische Daten] A Southwest Oncology Group study [Robert Whitehead, Robert Earhart, Thomas Fleming, Phyllis Goodman, John Macdonald, Theodore Pollock, James Ungerleider] Summary: In this phase II trial, menogaril was administered to patients with metastatic colon cancer at a dose of 200 mg/m2 IV over one hour with cycles repeated every 28 days provided the absolute granulocyte count was ≥ 2000 cells/μl. Dose adjustments up or down were made depending upon nadir counts. Twenty-four patients were entered on this study with 21 eligible and evaluable for response. There was 1 CR lasting four and one-half months and 1 PR lasting three months for an overall CR \s+ PR rate of 10% with a 95% confidence interval of 1% to 30%. Six patients (29%) had stable disease and 13 (62%) progressed. Median survival is 13.1 months. Toxicity was primarily hematologic with two cases of life-threatening leukopenia (< 1000 cells/μl) and one case of life-threatening granulocytopenia (< 250 cells/μl) among the 21 eligible patients, and one case of life-threatening leukopenia and granulocytopenia in one ineligible patient. There were no deaths due to treatment. Kluwer Academic Publishers, 1990 menogaril nationallicence colorectal carcinoma nationallicence Whitehead Robert University of New Mexico, USA aut Earhart Robert The Upjohn Company, USA aut Fleming Thomas Southwest Oncology Group Statistical Center Seattle, USA aut Goodman Phyllis Southwest Oncology Group Statistical Center Seattle, USA aut Macdonald John University of Kentucky Medical Center, USA aut Pollock Theodore Columbus CCOP, USA aut Ungerleider James Dayton CCOP, USA aut Investigational New Drugs Kluwer Academic Publishers 8/3(1990-08-01), 295-297 0167-6997 8:3<295 1990 8 10637 https://doi.org/10.1007/BF00171840 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF00171840 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Whitehead Robert University of New Mexico, USA aut NATIONALLICENCE 700 1- Earhart Robert The Upjohn Company, USA aut NATIONALLICENCE 700 1- Fleming Thomas Southwest Oncology Group Statistical Center Seattle, USA aut NATIONALLICENCE 700 1- Goodman Phyllis Southwest Oncology Group Statistical Center Seattle, USA aut NATIONALLICENCE 700 1- Macdonald John University of Kentucky Medical Center, USA aut NATIONALLICENCE 700 1- Pollock Theodore Columbus CCOP, USA aut NATIONALLICENCE 700 1- Ungerleider James Dayton CCOP, USA aut NATIONALLICENCE 773 0- Investigational New Drugs Kluwer Academic Publishers 8/3(1990-08-01), 295-297 0167-6997 8:3<295 1990 8 10637 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer